Lipocine’s Phase 2 LPCN 1148 study results ‘compelling,’ says Cantor Fitzgerald

Cantor Fitzgerald analyst Jennifer Kim reiterated the firm’s Overweight rating or $33 price target on Lipocine after the company announced positive topline results from its Phase 2 proof of concept study of LPCN 1148, its oral candidate for the clinical management of cirrhosis. The efficacy and safety profile demonstrated in this sick patient population is compelling, and, if replicated in a larger study, would address a large unmet need and market opportunity, the analyst tells investors in a research note.